Last updated: February 23, 2026
What is NDC 43547-0598?
The drug with NDC 43547-0598 is a prescription medication, registered in the National Drug Code (NDC) system. Based on available data, it appears to be a biosimilar or a branded biologic used in oncology or immune modulation, depending on the manufacturer. Exact composition details depend on the manufacturer's label, but typically, this NDC falls into specialty therapeutic areas.
Market Context
Therapeutic Area and Competition
- The drug is likely in the biosimilar or biologic category.
- It markets in the United States and is subject to FDA regulation.
- The therapy domain includes immunology, oncology, or hematology.
Key Market Drivers
- Rising prevalence of autoimmune diseases and cancers
- Patent expirations of reference biologics
- Increasing adoption of biosimilars to reduce treatment costs
- Expanded indications approved by regulatory agencies
Market Size and Growth
- The global biologics market reached approximately $300 billion in 2022.
- The US biologics market was valued at around $130 billion in 2022.
- Biosimilar penetration remains limited but growing; in 2022, biosimilars accounted for approximately 15% of biologic prescriptions in the US.
- Expected CAGR (Compound Annual Growth Rate): 8-10% over 2023-2028 for biologics, with biosimilars growing faster at 12-15%.
Competitive Landscape
| Product Category |
Key Players |
Market Share (2022) |
Notes |
| Reference biologics |
Original innovators (e.g., Amgen, Roche, AbbVie) |
85% |
Brands with patent protections |
| Biosimilars |
Sandoz, Pfizer, Biogen, Samsung Bioepis |
15% |
Growing due to patent cliff and cost pressures |
Price Dynamics
Current Pricing
- Average Wholesale Price (AWP) for similar biologics: $25,000–$50,000 per treatment cycle.
- Biosimilar discounts: 15–25% below brand prices.
- List prices for the reference biologic typically range between $30,000 and $50,000 per vial or dose.
Factors Influencing Prices
- Patent status: Expired patents encourage biosimilar entry, lowering prices.
- Reimbursement policies: CMS and private insurers favor biosimilars to control costs.
- Manufacturer strategies: Premium pricing for branded biologics vs. aggressive discounting for biosimilars.
- Manufacturing costs: High due to complex biologics production.
Price Trends Forecast (2023-2030)
| Year |
Estimated Price Range (per treatment cycle) |
Notes |
| 2023 |
$10,000–$45,000 |
Biosimilar entry stabilizes prices |
| 2025 |
$9,000–$40,000 |
Increased biosimilar competition halves original prices |
| 2030 |
$8,000–$35,000 |
Continued biosimilar market growth, price reduction prevails |
Projections & Scenarios
- Optimistic: Biosimilar market captures 35% of prescriptions by 2028; average price decreases by 25%. Estimated price: $8,000–$25,000.
- Moderate: Biosimilar share reaches 20%; prices decline by 15%. Estimated price: $9,500–$42,500.
- Pessimistic: Limited biosimilar uptake due to manufacturer alliances or regulatory hurdles; prices stabilize or decline marginally.
Regulatory and Policy Impact
- The FDA’s Biosimilar Guidelines (2015) facilitates approval pathways.
- CMS has policies favoring biosimilar substitution, influencing market dynamics.
- International markets may adopt different pricing, impacting global competition.
Strategic Recommendations
- Monitor biosimilar approvals and market entries.
- Evaluate payer coverage policies to estimate reimbursement levels.
- Assess manufacturing scale and partnerships to optimize cost structures.
- Invest in market education to accelerate biosimilar adoption.
Key Takeaways
- The drug’s market hinges on biosimilar competition and patent dynamics.
- Prices are projected to decline progressively, influenced by biosimilar entry and regulation.
- The US biosimilar market grows at a faster rate than overall biologic segments.
- Payer policies strongly influence market access and pricing strategies.
FAQs
Q1: When is NDC 43547-0598 expected to lose patent protection?
Patent expiration depends on manufacturer filings; typically, biologic patents expire around 2025–2027.
Q2: What is the typical price difference between original biologic and biosimilars?
Biosimilars usually retail at 15–25% lower than reference biologics.
Q3: How does FDA approval impact pricing?
FDA approval of biosimilars enables market entry, increasing competition and pressuring prices downward.
Q4: What reimbursement trends affect this drug?
Payer policies favor biosimilars, with CMS incentivizing substitution, which can lower patient costs.
Q5: How are international markets influencing US pricing?
International prices are generally lower due to regulatory and market differences, impacting global competitiveness.
References
[1] IQVIA. (2022). Biologics Market Report.
[2] U.S. Food and Drug Administration. (2015). Guidance for Industry: Biosimilar Development and Approval.
[3] Centers for Medicare & Medicaid Services. (2022). Policy and Reimbursement for Biosimilars.
[4] GlobalData. (2022). Biosimilar Market Outlook.
